Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹3,937Cr
Rev Gr TTM
Revenue Growth TTM
8.53%
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | 27.0 | 16.4 | 11.5 | 10.7 | 14.8 | 13.5 | 10.3 | 6.0 | 6.0 | 4.9 | 8.9 | 14.4 |
| 241 | 259 | 267 | 259 | 266 | 281 | 286 | 273 | 272 | 292 | 310 | 310 |
Operating Profit Operating ProfitCr |
| 12.1 | 15.4 | 15.9 | 15.4 | 15.4 | 19.3 | 18.2 | 16.1 | 18.4 | 20.0 | 18.7 | 16.7 |
Other Income Other IncomeCr | 5 | 4 | 4 | 4 | 5 | 5 | 6 | 5 | 6 | 7 | 7 | 7 |
Interest Expense Interest ExpenseCr | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 1 |
Depreciation DepreciationCr | 10 | 10 | 10 | 10 | 10 | 11 | 11 | 11 | 11 | 10 | 11 | 11 |
| 27 | 40 | 44 | 41 | 42 | 60 | 57 | 45 | 55 | 68 | 66 | 56 |
| 7 | 10 | 11 | 11 | 10 | 15 | 15 | 12 | 14 | 17 | 17 | 15 |
|
Growth YoY PAT Growth YoY% | 30.5 | 50.4 | 30.7 | 40.9 | 57.1 | 46.8 | 29.1 | 11.4 | 31.6 | 14.9 | 16.6 | 25.0 |
| 7.2 | 9.9 | 10.4 | 9.6 | 9.9 | 12.9 | 12.1 | 10.1 | 12.3 | 14.1 | 13.0 | 11.0 |
| 2.2 | 3.3 | 3.6 | 3.2 | 3.4 | 4.9 | 4.6 | 3.6 | 4.5 | 5.6 | 5.4 | 4.5 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|
|
| 5.4 | 5.7 | 1.4 | -1.7 | 4.7 | 5.4 | -26.2 | 44.8 | 23.7 | 13.3 | 9.0 | 7.0 |
| 630 | 676 | 687 | 680 | 707 | 744 | 573 | 774 | 948 | 1,051 | 1,112 | 1,184 |
Operating Profit Operating ProfitCr |
| 11.9 | 10.5 | 10.3 | 9.7 | 10.3 | 10.4 | 6.6 | 12.9 | 13.7 | 15.5 | 18.0 | 18.4 |
Other Income Other IncomeCr | 1 | 2 | 0 | 1 | 0 | 1 | 1 | 3 | 10 | 17 | 23 | 28 |
Interest Expense Interest ExpenseCr | 8 | 7 | 8 | 9 | 7 | 6 | 3 | 3 | 4 | 4 | 6 | 6 |
Depreciation DepreciationCr | 28 | 35 | 31 | 31 | 30 | 33 | 33 | 35 | 39 | 40 | 44 | 43 |
| 50 | 39 | 41 | 34 | 45 | 48 | 4 | 79 | 117 | 166 | 216 | 246 |
| 17 | 14 | 15 | 13 | 16 | 5 | 2 | 20 | 31 | 42 | 55 | 63 |
|
| -8.3 | -24.8 | 7.4 | -19.6 | 34.6 | 53.5 | -94.7 | 2,415.9 | 47.0 | 43.9 | 29.9 | 13.6 |
| 4.5 | 3.2 | 3.4 | 2.8 | 3.6 | 5.3 | 0.4 | 6.6 | 7.8 | 10.0 | 11.9 | 12.6 |
| 3.5 | 2.7 | 2.9 | 2.3 | 3.1 | 4.8 | 0.3 | 6.4 | 9.4 | 13.5 | 17.6 | 19.9 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|
Equity Capital Equity CapitalCr | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 |
| 103 | 132 | 139 | 141 | 152 | 176 | 181 | 234 | 288 | 386 | 505 | 567 |
Current Liabilities Current LiabilitiesCr | 194 | 191 | 186 | 138 | 124 | 140 | 116 | 94 | 130 | 165 | 179 | 223 |
Non Current Liabilities Non Current LiabilitiesCr | 53 | 46 | 42 | 62 | 54 | 42 | 43 | 43 | 46 | 80 | 76 | 73 |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 149 | 152 | 158 | 133 | 136 | 141 | 141 | 157 | 223 | 308 | 431 | 594 |
Non Current Assets Non Current AssetsCr | 293 | 308 | 301 | 299 | 287 | 308 | 291 | 304 | 332 | 415 | 420 | 360 |
Total Assets Total AssetsCr |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | 64 | 62 | 28 | 48 | 75 | 86 | 27 | 94 | 144 | 200 | 157 |
Investing Cash Flow Investing Cash FlowCr | -29 | -33 | -22 | -30 | -17 | -40 | -19 | -74 | -108 | -158 | -111 |
Financing Cash Flow Financing Cash FlowCr | -35 | -30 | -5 | -17 | -44 | -43 | -3 | -3 | -26 | -32 | -46 |
|
Free Cash Flow Free Cash FlowCr | 35 | 29 | 5 | 17 | 58 | 46 | 6 | 65 | 100 | 131 | 120 |
| 197.9 | 254.8 | 105.3 | 226.0 | 264.6 | 198.2 | 1,150.6 | 160.9 | 167.7 | 161.5 | 97.4 |
CFO To EBITDA CFO To EBITDA% | 75.8 | 78.4 | 35.1 | 65.5 | 93.1 | 100.1 | 66.6 | 82.5 | 95.9 | 103.5 | 64.2 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 510 | 476 | 486 | 443 | 352 | 311 | 493 | 536 | 713 | 1,574 | 3,539 |
Price To Earnings Price To Earnings | 17.5 | 19.5 | 18.6 | 21.0 | 12.4 | 7.1 | 215.0 | 9.2 | 8.3 | 12.7 | 22.0 |
Price To Sales Price To Sales | 0.7 | 0.6 | 0.6 | 0.6 | 0.5 | 0.4 | 0.8 | 0.6 | 0.7 | 1.3 | 2.6 |
Price To Book Price To Book | 2.6 | 2.1 | 2.1 | 1.9 | 1.4 | 1.2 | 1.8 | 1.6 | 1.9 | 3.3 | 5.9 |
| 6.3 | 6.5 | 6.9 | 6.8 | 4.3 | 3.4 | 11.6 | 4.1 | 3.9 | 7.2 | 13.3 |
Profitability Ratios Profitability Ratios |
| 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| 11.9 | 10.5 | 10.3 | 9.7 | 10.3 | 10.4 | 6.6 | 12.9 | 13.7 | 15.5 | 18.0 |
| 4.5 | 3.2 | 3.4 | 2.8 | 3.6 | 5.3 | 0.4 | 6.6 | 7.8 | 10.0 | 11.9 |
| 25.1 | 17.0 | 16.5 | 14.7 | 19.9 | 19.9 | 2.8 | 24.9 | 31.8 | 33.3 | 35.4 |
| 16.7 | 10.9 | 11.4 | 9.1 | 11.6 | 16.3 | 0.8 | 18.0 | 22.7 | 25.9 | 27.0 |
| 7.4 | 5.3 | 5.7 | 4.9 | 6.7 | 9.7 | 0.5 | 12.7 | 15.5 | 17.1 | 18.9 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
### **Overview**
Indraprastha Medical Corporation Ltd (IMCL), operating as **Indraprastha Apollo Hospitals**, is a leading integrated healthcare provider in India and a flagship entity within the **Apollo Hospitals Group**—India’s largest and first corporate healthcare chain, established in 1983. With a strong foundation in clinical excellence, technological innovation, and patient-centric care, IMCL continues to strengthen its market leadership through strategic expansion, digital transformation, and a focus on preventive and precision medicine.
Designated a trusted destination for **Medical Value Travel (MVT)**, IMCL has treated patients from over 150 countries for more than four decades. Its reputation for high-quality outcomes, international safety standards, and affordable care positions it as a key player in India’s push toward becoming a global healthcare hub.
---
### **Integrated Healthcare Delivery Model: "One Apollo"**
Apollo is unifying its vast network of:
- Hospitals
- Clinics
- Diagnostics
- Pharmacies
- Digital platforms
- Home care
- Insurance services
Under the **“One Apollo”** initiative, creating a seamless, **end-to-end care continuum** across all touchpoints. This integrated model enhances patient experience, operational efficiency, and care coordination.
---
### **Digital & Technological Innovation**
IMCL is accelerating its digital transformation through advanced technology and strategic partnerships:
- **"One Apollo" Tech Integration**:
Collaboration with **Microsoft** enables cloud-based systems and intelligent automation to streamline clinical workflows and enhance data interoperability.
- **Apollo 24|7 – Digital Health Powerhouse**:
- Over **33 million registered users** (up from 25 million in 2023)
- Offers **virtual consultations within 15 minutes**, including emergency care
- Medicine delivery in **under 2 hours across 19,000+ pincodes**
- Home sample collection, **digital EMR (health vault)**, diagnostics, and specialist treatments
- Serves as a **360-degree digital health ecosystem**
- **"Ask Apollo" Platform**:
Streamlines appointment booking and online consultations for outpatient needs.
---
### **Centers of Excellence (COEs) & Clinical Leadership**
IMCL operates **specialized COEs** in:
- Cardiac Sciences
- Neuro Sciences
- Oncology
- Orthopedics
- Gastro Sciences
- Transplants
- Pediatrics
- Genomics
Each COE features:
- Multidisciplinary care teams
- Sub-specialty expertise
- Rigorous performance metrics
- Academic programs and clinical research
- Emphasis on **advanced procedures and innovative therapies**
> **New COE – Genomic Medicine (launched 2022)**:
> A dedicated center offering **precision medicine, early disease prediction**, and preventive genomics, led by world-renowned geneticists and supported by DNB training and clinical trials.
---
### **Advanced Medical Technologies**
IMCL remains at the forefront of adopting cutting-edge medical equipment:
- **EDGE Radiotherapy System with HyperArc™**
- Delivers **sub-millimeter precision** in radiosurgery
- High dose rate (2400 MU/min) enables **shorter treatment times**
- Advanced imaging (IGRT, CBCT) and **non-coplanar beams** for complex tumors (brain, spine, lung, liver, prostate)
- Minimizes damage to healthy tissue, improves outcomes
- **ZAP Gyroscopic Radiosurgery System**
- **First in South Asia**, ZAP allows **non-invasive brain and head/neck cancer treatment** using optimized LINAC and self-shielding—**no radiation bunker required**
- Scheduled deployment of **Zap-X** for enhanced accessibility
- **Robotic Surgery Advancements**
- **Da Vinci Xi Surgical System** with thinner arms, 3DHD vision, and enhanced flexibility for minimally invasive procedures
- Apollo leads India in **robot-assisted surgeries**, including complex cardiac and oncology procedures
- **Other Innovations**:
- 3D Electrophysiology System (EPS)
- SpyGlass™ for advanced gastroenterology
- TCD, C-Mac video laryngoscope, and lithotripsy upgrades
---
### **Preventive & AI-Powered Care**
- **Apollo ProHealth**:
- An **AI-driven preventive care platform** serving **over 1 million individuals**
- Uses **AI-CVD risk prediction model** and **Apollo Clinical Intelligence Engine (CIE)** to detect silent risks (e.g., heart disease, diabetes, stroke)
- Offers **personalized health insights, lifestyle coaching**, and continuous monitoring
- Linked to **periodic health assessments** and early intervention protocols
- **AI Integration Across Care Spectrum**:
AI tools now support:
- Risk prediction
- Early diagnosis
- Personalized treatment plans
- Smart inpatient room automation
- Enhanced clinical decision-making
> Mission: Shift from **reactive** to **proactive, predictive, and personalized healthcare**.
---
### **Telemedicine & Remote Care Infrastructure**
Apollo operates **India’s most extensive telehealth network**:
- **Integrated Telemedicine Services**:
- Primary and specialist consults
- Tele-radiology, tele-ECG, e-ICU, and ophthalmology
- **Apollo Connect Program**:
- Integrates **hospitals and nursing homes nationwide** to improve care coordination and clinical skilling
- Supports **decentralized, localized treatment**
- **Command Stations**:
Located at flagship hospitals, manage **thousands of teleconsultations daily**
- **Apollo Emergency Ambulance Network (1066)**:
Provides **immediate doorstep care**, integrated with hospital command centers
- **Home Healthcare Services**:
Includes nurse/doctor visits, physiotherapy, geriatric care, pre/post-op support, and home diagnostics
---
### **Retail & Alternative Care Delivery**
Reflecting evolving consumer preferences, Apollo is expanding **capital-efficient, high-return healthcare formats**:
- **Neighborhood Clinics**
- **Single-Specialty Centers** (fertility, maternity, ophthalmology, dental, dialysis, diabetic care)
- **Daycare & Birthing Centers**
- **Diagnostic Chains & Dental Clinics**
- **Home Services & Short-Stay Centers**
> These formats offer **lower capex, faster breakeven**, and better specialization—increasing reach and accessibility, particularly in urban and semi-urban areas.
---
### **Global Outreach & Partnerships**
- **Medical Value Travel (MVT)**:
IMCL is a top MVT destination, offering **world-class care at ~1/10th the cost** of Western countries. Global market valued at **$600 billion**—a key growth avenue.
- **Government of Tripura Partnership**:
Provides **free pediatric heart surgeries** to underserved populations
- **International Collaboration**:
Joint programs with **Mayapada Healthcare Group (Indonesia)** in oncology, cardiology, neurology, and transplants
- **Academic Alliance**:
Partnership with the **University of Leicester** to develop future clinical leaders and advance research
---
### **Brand Strength & Talent Attraction**
- Recognized for **clinical excellence, safety, and patient trust**
- Strong employer brand attracts **top-tier medical and managerial talent** from India and abroad
- Physicians known for **high success rates in critical and complex surgeries**
---
### **Public-Private Partnerships (PPPs) & Social Impact**
- Played a vital role during the pandemic via **Project Kavach**:
- AI-based COVID screener
- Teleconsultations, home care, hotel quarantine model
- Treated **over 63,000 inpatients**, supported **16 state governments** and central agencies
- Expanded preventive outreach via **mobile clinics (e.g., Samsung-Apollo Mobile Clinic)** for early NCD screening in urban areas
---